Leukemia is an acquired genetic disease caused by the accumulation of chromosomal abnormalities which modify either the biochemical property or the level of expression of proteins. Frequent genetic abnormalities identified in human leukemia are chromosomal rearrangements such as chromosomal translocations and inversions. Chromosome band 3q26 is the site of the breakpoint of recurring translocations and inversions observed in patients with myeloid leukemias. Two genes located at 3q26 have been implicated in development or progression of myeloid leukemia. They are MDS1 and EVI1. MDS1, first identified as part of a fusion transcript resulting from the t(3;21)(q26;q22), encodes a small protein of unknown function. EVI1 encodes a zinc finger protein inappropriately overexpressed by chromosomal rearrangements (in man) or by retroviral insertion (in the mouse). Both genes are rearranged by the t(3;21)(q26;q22) and by the t(3;12)(p13;q22). As a result of the translocation, they are expressed as fusion genes either with AML1 or with TEL. EVI1 and MDS1 are unusual in that they can either encode separate proteins, or they can be expressed as one protein which we named MDS1/EVI1. EVI1 and MDS1/EVI1 have opposite functions as transcription factors. In this report, we review the current information on the two genes, and on their involvement in myeloid leukemia.
Introduction
Cancer and leukemia are genetic diseases caused by mutations and abnormalities in the chromosomes. The mutations are either inherited and are present in somatic cells and germline, or they are caused by environmental factors and are acquired, and therefore they are detected only in somatic cells. In leukemia, the abnormalities are often acquired and observed only in the leukemic clone, and they consist of structural aberrations as translocations, inversion, deletions or duplications, and numerical aberrations, with gain or loss of entire chromosomes. There is convincing evidence that in many cases more than one mutation may be required for the progression from normal hematopoietic precursor cells to leukemic cells. The study of recurring chromosomal abnormalities in leukemia has identified many regions of chromosomes that are likely to contain genes important both in normal hematopoietic development and in the generation of various neoplasia. One of the genes associated with both murine and human acute myeloid leukemia (AML) is the Evi1 gene. This gene was originally identified during studies of insertional activation by replication-competent, non-acute transforming retroviruses leading to myeloid transformation. These studies showed that a number of interleukin-3 (IL-3)-dependent murine cell lines contained retroviral insertion in Evi1, a common site of integration identified in myeloid tumors of AKXD Correspondence: G Nucifora; Fax: 708 327 3342 Received 16 July 1997; accepted 9 September 1997 mice. 1 Subsequently, it was shown in the mouse that viral insertions in this locus activated the expression of a novel gene which was called Evi1. 2 The Evi1 locus was later mapped to murine chromosome 3. 3 In addition, analysis of Cas-Br-E MuLV integration sites showed that integration at the Evi1 locus induced myeloid leukemia in NIH/Swiss and NSF mice. 1, 3, 4 Retroviral insertions into the murine Evi1 locus occur almost exclusively in two well-defined regions upstream of the gene, and result in the inappropriate expression of Evi1 through promoter activation by the retroviral long terminal repeat (LTR). 2 The preferential integration site closest to the coding region of the gene is either within a 2 kb stretch of DNA which encompasses exon 1 of Evi1, or between noncoding exons 1 and 2 of the gene, 2 and it was suggested that Evi1 transcription could be initiated from the retroviral promoter inserted into this region. Evi1 expression may also be activated from a second insertion site in the Cb-1/Fim3 locus, located 90 kb upstream of exon 1 and identified independently in two laboratories. [5] [6] [7] In the mouse, this locus is genetically linked to Evi1 as no recombination was observed in interspecific backcrossed mice. Because retroviral insertions at this site act from such a distance to activate Evi1 expression, the activation probably occurs through the viral enhancer.
Although activation of the human EVI1 gene occurs frequently in myeloid leukemia through chromosomal rearrangements, there are no confirmed reports of EVI1 activation by retroviral insertion in humans. The human EVI1 gene was isolated using a murine Evi1 cDNA to probe a human library, 8 and was mapped to human chromosome 3, band 3q24-q28.
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EVI1 is a sequence-specific DNA-binding protein
Aside from the first exon, which is not translated, the murine and human cDNAs are 91 and 94% homologous in nucleotide and amino acid sequence respectively. 8 Interestingly, although both in human and murine cDNAs the first methionine is encoded in exon 3, in which translation is predicted to start, the DNA sequence of the second exon is highly conserved between the two species (Ͼ90%), and contains an open reading frame (ORF) in frame with the predicted translation start site in the third exon. The predicted size of the protein is consistent with the size observed from Western blot analyses of cellular extracts which show a major band of about 145 kDa.
9
EVI1 encodes a nuclear DNA binding protein 9, 10 with two domains containing two sets of seven and three repeats of the Cys 2 Hys 2 type of zinc finger motif. 2 The domain consisting of seven zinc finger repeats is localized in the amino terminus whereas the second domain, containing three zinc finger motifs, is found toward the carboxyl terminus (Figure 1a ). This type of zinc finger is frequently seen in transcription factors involved in other leukemia-associated chromosomal translocations. Some examples are BCL6, identified in several rearrangements at 3q27, [11] [12] [13] PLZF, fused to RAR␣ in the t(11;17), 14 and ETO, consistently fused to AML1 in the t(8;21). [15] [16] [17] A very high homology was observed between the zinc fingers of EVI1 and those of the C. elegans differentiation protein egl- 43, 18 suggesting that the proteins may recognize and bind to similar targets ( Figure 1a ). Egl-43 is involved in correct migration of hermaphrodite sensory neurons (HSN) during embryonic development. 18 Both the zinc finger domains of EVI1 recognize and bind to specific DNA consensus sequence. The first zinc finger domain of EVI1 recognizes a consensus of 15 nucleotides consisting of GA(C/T)AAGA(T/C)AAGATAA. 19 The first three fingers of the proximal domain do not bind the above sequence, but contribute to binding by conferring a relative specificity for GACAA Vs GATAA in the first position. 19 The second set of three zinc fingers bind the consensus sequence GAAGAT-GAG. 20 EVI1 also exists as an 88 kDa alternatively spliced form, which is missing zinc fingers 6 and 7, in both humans 8 and mouse. 21 Expression of this alternatively spliced form has been found to be induced approximately 16-fold by elevated levels of intra-cellular cAMP and down-regulated by TPA in the human renal cell carcinoma cell line A704.
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EVI1 also contains a highly acidic domain at the carboxyl terminus ( Figure 1a) . Although acidic domains are often identified in transcription factors and usually are part of transcription activation domains, there are no data which indicate conclusively that the acidic domain of EVI1 is necessary for transcription regulation.
EVI1 expression and function
The pattern of Evi1 expression in embryonic and adult mouse tissues was first reported by Perkins et al. 23 Their results showed that in the mouse embryo, Evi1 is expressed at high levels in the urinary system and in the Mullerian ducts, in the lung, and in the heart. In addition, Evi1 was detected in the developing limbs, primary fetal cells, differentiating red blood cells and developing oocytes in the ovary. 23, 24 Northern blot analysis of adult human tissues has shown that EVI1 is expressed abundantly in kidney, lung, pancreas and ovaries, 25 and to a lesser extent in several other tissues, including skeletal muscle.
Because of the spatial and temporal restricted pattern of expression of Evi1, it was suggested that this gene plays an important role in mouse development 23 and could be involved in organogenesis, cell migration, cell growth, response to physiological state, and differentiation. This is confirmed by recent work showing that the disruption of the full-length Evi1 transcript by targeted mutagenesis of embryonic stem cells results in the death of mutant embryos at approximately 10 5 . 26 Homozygous Evi1-/-embryos were readily identified by hemorrhaging and malformation of the paraxial mesoderm. Histological analysis revealed widespread hypocellularity, defective myotome formation, defects in the neural ectoderm, and failure of the peripheral nervous system to develop. The cellular proliferation defects noted in mutant embryos would support the involvement of Evi1 in dysregulated cell growth observed in retrovirus-induced leukemias. 26 Studies of the function of murine and human EVI1 in bone 27, 28 Some of these studies utilized the IL-3-dependent murine cell line 32Dc13. 32Dc13 cells are myeloid precursor cells which differentiate into granulocytes in response to G-CSF. 29 Although these cells normally express the endogenous Evi1 due to retroviral integration, 30 they will differentiate into granulocytes in response to G-CSF. 29 However, infection or transfection of 32Dc13 cells with constructs expressing human or murine EVI1 cDNA leads to block of G-CSF-dependent differentiation, and to inability of the cells to express myeloperoxidase and to differentiate to granulocytes. 27, 28 Expression of additional EVI1 in erythroid progenitors can also result in the loss of erythropoietin responsiveness. 28 Because it was shown that EVI1 can repress GATA-1-dependent transactivation in transient CAT assays, 28 it was suggested that the block in erythroid differentiation may be caused by transcriptional repression of a subset of GATA-1 target genes caused by the inappropriate expression of EVI1. 28 The function of EVI1 as a transcriptional regulator is quite complex. Although work from several groups, including ours, has shown that EVI1 will repress a number of synthetic promoters, the biological promoters targeted by EVI1 are not known. Thus, the genes affected and regulated by EVI1 are not identified yet. However, recently it was shown that one of the downstream effects of EVI1 in NIH 3T3 and P19 cells is to increase the expression of endogenous c-Jun and c-Fos resulting in activation of AP-1 and increased cellular proliferation. The indirect activation of c-Fos requires the second zinc finger domain of EVI1, but there was no report of binding of EVI1 to the promoter, and the indirect mechanism by which EVI1 activates the c-Fos promoter were not clarified.
31 EVI1 can activate three-fold a promoter containing the target sites of both groups of zinc fingers. However, activation depends on the binding of the carboxyl terminal domain of zinc fingers to the second consensus, and not on binding of the amino domain of zinc fingers to the first consensus. 32 In contrast, studies using CAT reporters that contained either the first or second EVI1 target sites upstream of the HSVtk promoter found that EVI1 dramatically expressed the activity of these reporters. 28, 33 More recently, studies by Bartholomew et al 34 showed that EVI1 represses synthetic promoters in which the zinc fingers consensus site was cloned upstream of the herpes simplex virus (HSV) thymidine kinase (tk) promoter or of the adenovirus minimal promoter, confirming the role of EVI1 as transcriptional repressor. In addition, these investigators showed that the repression function is localized in a stretch of proline-rich residues located between the two groups of zinc fingers (Figure 1a ), and it can be completely abolished by an internal deletion spanning the proline-rich stretch.
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Involvement of EVI1 in myeloid leukemias
The inappropriate activation of EVI1 in hematopoietic cells has long been implicated in development or progress of myeloid leukemias in man and mouse. 87, 88 In human leukemias, such activation often results from chromosomal rearrangements at 3q26, which is the site of the EVI1 locus. 35, 36 The most frequent rearrangements are those that involve chromosome 3 at bands 3q21 and 3q26, and result in the t(3;3)(q21q26) and in the inv(3)(q21q26). So far, by using pulsed field gel electrophoresis (PFGE) and fluorescence in situ hybridization (FISH) analyses, the breakpoints of the 3;3 translocations have been mapped 5Ј of EVI1, whereas the breakpoints of the inv(3) have been mapped 3Ј of the gene (Figure 2) . 37, 38 This defined orientation of the two breakpoints on chromosome 3 suggested that the activation could occur through inappropriate juxtaposition of EVI1 to the regulatory sequence of a gene located at 3q21. After cloning and molecular analysis of breakpoint junctions of the t(3;3) and inv(3), it was determined that both these rearrangements juxtapose the enhancer of the constitutively expressed housekeeping gene Ribophorin I to the coding region of EVI1. 38 The breakpoints of the t(3;3) are not localized to a restricted region upstream of EVI1, but occur over a genomic region of 13-300 kb 5Ј of the gene, and lead to full activation of the gene by juxtaposition of the Ribophorin I enhancer. 37, 38 Although inappropriate activation of genes caused by chromosomal rearrangements over such a large distance are not very common, they have been reported before.
In general, defects of 3q in bands q21 and q26 have been reported in patients with AML/MDS and in patients with refractory anemia with excess blasts in transformation (RAEB-T). Patients who express EVI1 often have monosomy of chromosome 7 or deletions of the long arm of chromosome 7, and, less frequently, deletions in chromosome 5. The most characteristic clinical features of these patients are elevated platelet counts, marked hyperplasia with dysplasia of the megakaryocytes, and poor prognosis. Although disturbance of thrombopoiesis is not systematically observed in all patients with 3q21q26 rearrangements, the frequency of patients with these characteristics brings further evidence to the existence of a cytogenetic syndrome involving bands q21 and q26 simultaneously and referred to as q21q26 syndrome. 36, [39] [40] [41] [42] 47, 89 Because monosomy 7 has been detected in AML patients who do not express EVI1, alteration in chromosome 7 may contribute to the evolution of AMLs that already involve EVI1. 28 There are no unique morphologic characteristics in cells that express EVI1, and the leukemic cells have been described as FAB M0, M1, or M2. 28 Some of the cells examined were CD34-positive, suggesting that they were immature myeloid cells. This agrees with the immature phenotype characteristic of murine myeloid cells expressing EVI1.
Activation of EVI1 also occurs as a result of translocations involving a chromosome other than 3. The chromosomal breakpoints of two such cases have been cloned, that of the t(3;21)(q26;q22) and that of the t(3;12)(q26;p13) ( Figure 2) . 25, 43, 44 These translocations have been reported in MDS or AML, or in CML during the blast crises. [44] [45] [46] 48, 49 In either case, the translocation leads to constitutive expression in myeloid cells of a fusion protein of which the entire EVI1 represents the carboxyl end, rather than to overexpression of EVI1 as seen in the t(3;3) and inv(3). The t(3;21) leads to fusion between the DNA-binding domain of the transcription factor AML1 (also known as CBFA2 [50] [51] [52] ) and the second exon of EVI1, 25, 43 whereas the t(3;12) involves the fusion of the amino terminus of the ETS protein TEL 53, 54 to the second exon of EVI1. 55 Both AML1 and TEL are transcription factors associated with a large number of recurring chromosomal translocations. [56] [57] [58] However, whereas rearrangements of AML1 and TEL have been detected in myeloid and lymphoid leukemias, the rearrangements of EVI1 have been associated exclusively with myeloid leukemias. After cloning of the breakpoints of the 3;12 and 3;21 translocations and analysis of the chimeric cDNAs, new identical sequences were identified inserted between those of AML1 or TEL and the second exon of EVI1 (Figure 3) . These new sequences mapped to chromosome 3q26. Because we identified these new sequences in a patient with MDS, we named the sequences MDS1. 25 The nature of these sequences will be discussed in the next section. The fusion genes resulting from the t(3;21) and t(3;12) have been named AML1/MDS1/EVI1 25 and TEL/MDS1/EVI1 respectively, 55 and in both cases they are transcribed on the der(3) chromosome by the promoter either of AML1 or of TEL. The predicted translation of the two fusion genes includes MDS1 and the second exon of EVI1, and add about 190 amino acids to the N-terminus of EVI1 (Figure 3) . Fusion transcripts in which the MDS1 region was spliced out have been detected, but they lead to truncated proteins which do not include EVI1 because of loss of reading frame. 55 As in the t(8;21) detected in AML-M2, [59] [60] [61] in the t(3;21) the breakpoint on chromosome 21 is consistently downstream of the DNA-binding domain of AML1. Thus, the predicted fusion protein resulting from the translocation contains EVI1 fused downstream of the DNA-binding domain of AML1 (Figure 3) . The breakpoint in the TEL gene is very close to the N-terminus of TEL, and the fusion gene results in a predicted protein which contains only about 50 amino acids upstream of EVI1 (Figure 3 ). Because TEL is expressed in most tissues and cell lines examined, it is not clear whether the fusion of TEL to EVI1 adds new functional domain(s) to EVI1 (thereby modifying its biochemical properties), or whether the fusion provides simply a heterologous promoter from which EVI1 is inappropriately expressed in the cell. Functional studies of TEL/MDS1/EVI1 to address this question are currently in progress in our laboratory.
AML1/MDS1/EVI1 is the fusion protein involving EVI1 which has been studied most extensively. Because this chimeric protein contains at least two separate potential DNAbinding sites (one from AML1, and another one consisting of the zinc finger domains of EVI1) and because both DNA-binding domains recognize different target sites, it is possible that the fusion protein could regulate inappropriately at least two types of promoters. Using reporter gene assays, we have shown that AML1/MDS1/EVI1 can indeed interfere and repress the response of a promoter to activation by the normal 
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. 62 By analyzing the response of the reporter gene to increasing amounts of AML1/MDS1/EVI1, we concluded that such repression is probably due to competition for the promoter site rather than to the dominant negative effect of the fusion protein. Thus it is possible that one of the mechanisms by which the fusion protein is leukemogenic is by dysregulating the expression of genes responding to AML1. Other investigators obtained similar results using the T cell receptor promoter in reported gene assays. 63 As we will discuss in more detail in the next section, we have also examined the response of a synthetic promoter-containing target site for the first zinc finger domain and determined that it is recognized and repressed by the fusion protein (unpublished results). Table 1 summarizes our results and those from other laboratories on the effects of various forms of EVI1 as transcriptional regulators.
As for other EVI1 rearrangements detected so far in human leukemia, the t(3;21) and t(3;12) are seen in patients with secondary leukemia or with CML during the blast crisis. 44, 64 Because the t(3;21) appears in CML only during the blast crisis of the disease, it is possible that activation of the gene may play a role in the progression of the disease from chronic to acute phase. However, recently a t(3;21) was detected in a patient with de novo childhood AML, 65 indicating therefore that this translocation is not restricted to adult patients with secondary leukemias or with CML during the acute phase. Activation of EVI1 was also reported in CML-BC patients with apparently normal chromosomes 3, [66] [67] [68] and results from several groups would indicate that a correlation exists between the activation of EVI1 (either as a fusion protein or by overexpression), and the progression of CML from the chronic to the acute phase. In addition, expression of EVI1 has been reported in ovarian and other cancers and in promyelocytic leukemia. 69, 70 In addition to the t(3;12) and t(3;21), EVI1 is involved in several other chromosomal translocations such as the t(2;3)(p13;q26), t(2;3)(q23;q26), t(3;7)(q26;q22), t(3;13) (q27;q13-14), and t(3;17)(q26;q22). [71] [72] [73] [74] [75] [76] [77] Although these rearrangements result in EVI1 overexpression, as determined by RT-PCR of the 3Ј region of the gene, it is not known yet whether the inappropriate expression relates to EVI1 only or to a fusion protein which includes EVI1. Table 2 summarizes the location of breakpoints in the rearrangements involving EVI1 which have been reported. 
The MDS1 gene
Identification of MDS1
MDS1 (myelodysplasia syndrome) encodes a small protein part of which was first identified in a fusion gene which results from the 3;21 translocation. 25 This translocation is unique in that it results in the expression of two or three fusion proteins with AML1. In addition to AML1/MDS1, we and others detected AML1/MDS1/EVI1 and AML1/EAP in patients with the t (3;21) . 25, 78, 79 By using PFGE and FISH analyses, the MDS1 locus was initially mapped at chromosome band 3q26, 150-300 kb upstream of EVI1 (Figure 2) . 25 Analysis of a multiple tissue Northern blot with MDS1 revealed two large bands of 5.8 and 6.2 kb identical in size to those observed with an EVI1 probe. 80 This suggested that MDS1 could be expressed in normal tissues as a transcript including EVI1. The existence of this MDS1/EVI1 transcript was confirmed with the isolation and sequencing of cDNA clones from normal human pancreas and kidney libraries. Analysis of the sequence showed that the clones contained an open reading frame in which MDS1 was spliced in-frame to the second exon of EVI1, resulting in a new gene which we named MDS1/EVI1. 80 The predicted translation of this longer ORF adds about 200 amino acids upstream of the previously reported start site of EVI1. 80 Analysis of the multiple tissue Northern blot with the MDS1 probe showed that, in addition to the 5.8 and 6.2 kb bands corresponding to MDS1/EVI1, three unique transcripts of about 1, 1.5 and 2 kb were also identified by the probe. This indicated that MDS1 can also be expressed as a unique gene encoding a small protein, presumably with transcripts of 1 to 2 kb. By screening normal cDNA libraries, we isolated two clones which correspond in size to the 1.5 and 2 kb transcripts, confirming the results of the Northern blot analysis. The two cDNAs have identical 5Ј untranslated regions (5Ј UTR) and they both contain the MDS1 exon(s) identified in TEL/MDS1/EVI1 and AML1/MDS1/EVI1, 25, 55 but differ at the 3Ј end, and have two alternative translated and non-translated 3Ј exons of MDS1. The two alternative isoforms of MDS1 result in two predicted proteins differing in their C-terminus by about 10-15 amino acids. 80 The pattern of expression of MDS1 is very similar to that of EVI1, with prominent bands in several tissues.
MDS1 and EVI1
In mouse and in man, the predicted translation of EVI1 begins in the third exon, in which the first methionine is encoded. However, the second exon is in-frame with the translation start codon and is very highly conserved between the two species (Ͼ90%). In MDS1/EVI1, 125 codons of MDS1 are spliced to the second exon of EVI1, resulting in the total addition of 188 codons upstream of the first methionine of EVI1. Sixty-three of the 188 codons derive from the second and part of the third exon of EVI1, upstream of the predicted translation start site. This new amino acid extension of EVI1 has about 40% homology to the N-terminus of seemingly unrelated proteins such as the retinoblastoma binding protein RIZ, 81, 82 the B cell factor B-LIMP-1 necessary for plasma cell differentiation, [83] [84] [85] and the C. elegans differentiation factor egl-43 ( Figure 4) . 18 The homology is concentrated mainly within three blocks of about 15 amino acids each, which are evenly spaced (Figure 4) . The domain has been named the PR domain, 80 and its conservation among the various proteins 
Figure 4
Alignment of PR domain sequences. Only identical residues (black background) between MDS1/EVI1 and other proteins are shaded. Dashes indicate sequence gaps. Conserved blocks A, B, and C are underlined. The arrows mark the boundaries between MDS1 and the second exon of EVI1, and between the second and third exons of EVI1. The boxed Met residue is the predicted translation start codon of EVI1 and is also indicated by an arrow. All the region upstream of this residue is lost following rearrangements which lead to overexpression of EVI1.
would suggest a common function. Thus, the homology between MDS1/EVI1 and egl-43 is much higher than previously thought, and it extends to include the amino terminus as well as one of the zinc finger domains. This would suggest that the two proteins, conserved through evolution, could be related. This is supported by experiments in C. elegans and in mice in which the genes were disrupted by homologous recombination. The results showed that disruption of egl-43 or Evi1 affects development of the nervous system. 18, 26 The identification of the cDNAs of MDS1, EVI1, and MDS1/EVI1 and the overall homology of MDS1/EVI1 to egl-43 raises the question of the nature and relationship of the three human genes. Figure 5 shows the position of the known critical exons participating in the splice junctions, and indicates how the various transcripts could be generated. Western blot analysis of human kidney proteins with polyclonal antiserum to MDS1 identified a protein with apparent size of about 28 kDa, somewhat larger than the predicted size of MDS1 (18 kDa). In addition, a minor doublet of about 38 kDa was also detected (unpublished results). Although cDNA clones encoding MDS1/EVI1 have been isolated from normal human libraries, 80 so far the immunodetection of MDS1/EVI1 has been reported only for proteins expressed after cell transfection, but not for the endogenous protein expressed in normal tissue. 86 As we noted earlier, other groups have reported on the transcription regulation effects of EVI1 (Table 1 ). This protein is generally considered a repressor, and a stretch of amino acid residues necessary for repression has been identified. 34 We have recently compared the transcriptional effects of EVI1 and MDS1/EVI1 using a genomic promoter containing several repeats of the AGATA sequence. By using reporter gene assays, we determined that whereas MDS1/EVI1 is an activator of the promoter, EVI1 is a strong repressor. We determined that the 188 amino acids extension at the N-terminus (PR domain) changes EVI1 from a strong repressor to a strong activator. 86 The extent of promoter activation by MDS1/EVI1 is comparable to that observed when using the erythroid factor GATA1 in similar assays. 28, 86 Our results also showed that EVI1 can repress activation by MDS1/EVI1 in addition to repression by GATA1. 86 The PR domain is responsible for the activating properties of MDS1/EVI1, and can also function by itself as a transcription activation domain when fused to a heterologous DNA binding domain such as that of Ga14. Analysis of deletion mutants indicated that the activation properties of the PR domain reside in the distal third of the domain. 86 These results taken together with the overall homology between MDS1/EVI1 and egl-43 would suggest that MDS1/EVI1, rather than EVI1, is the normal protein, and that leukemic transformation could be caused by the inappropriate expression of an altered activator which has become a repressor. In agreement with this hypothesis, our unpublished results on the transcriptional properties of the fusion protein AML1/MDS1/EVI1 show that this protein as well is a transcriptional repressor (Table 1) . Thus, mutation of MDS1/EVI1 either by truncation of the PR domain or by fusion to a heterologous N-terminal domain could lead to drastic change of its transcriptional properties.
Mechanisms of activation of EVI1 in chromosomal translocations
The model that we propose to explain the activation of EVI1 following the rearrangements is shown in Figure 6 , and is in part a modification of the model proposed by Suzukawa et al 38 when they cloned the breakpoints junction of the t(3;3) and inv(3). As they have proposed, the activation of EVI1 occurs in the t(3;3), in which the breakpoint separates MDS1 from the EVI1 sequence, and in the inv(3), in which the breakpoint is downstream of EVI1. In both cases, the activation is caused by juxtaposition of EVI1 to the enhancer of the Ribophorin gene. It is possible that the enhancer activates a cryptic promoter located close to the second exon of EVI1. Such hypothetical promoter is indicated by thin or thick gray arrows in lines 1, 2, and 3 of Figure 6 . In the inv(3), activation of the MDS1 promoter (indicated by the black arrow in Figure 6 ) does not occur because the enhancer is too far from it (about 500 kb).
Activation of EVI1 in the t(3;21) and (3;12) occurs through a completely different mechanism leading to fusion proteins. In these two cases, the chromosomal rearrangements result in a fusion of the promoter and proximal coding region of a partner gene (AML1 or TEL) to MDS1 ( Figure 6 , bottom line). According to this model, EVI1 is therefore unique among the genes involved at chromosomal breakpoints in that it can be inappropriately activated either by gene fusion or by gene truncation. As illustrated in Figure 3 , a consequence of the two mechanisms of activation is the consistent presence of the MDS1 sequence in the fusion proteins, but not in EVI1. Interestingly, though, both EVI1 and AML1/MDS1/EVI1 are repressors of MDS1/EVI1. Whether the presence of MDS1 is necessary to alter the biochemical properties of the chimeric protein or whether the fusion partner is just providing promoter functions is under investigation.
Conclusions
Since the identification of EVI1 as a gene associated with myeloid leukemia when inappropriately expressed, the involvement of this gene has been well documented in myeloid disorders in man and in the mouse. Although at first the activation of EVI1 in human leukemia was attributed solely to chromosomal rearrangements detected by cytogenetic analysis, lately several reports from various groups have made clear that inappropriate activation of EVI1 can result from events other than obvious chromosomal abnormalities, and activation of this gene has been associated with about 30% of patients with CML-BC with apparently normal chromosomes 3. It is not known what kind of alterations in these patients lead to the expression of EVI1. The understanding of the molecular events responsible for the activation of EVI1 in the transition from chronic to acute phase of CML is particularly difficult in large part because the promoter of this gene and the normal mechanisms of its activation are not known. The identification of MDS1/EVI1 significantly complicates the study of this gene because it raises the possibility that MDS1/EVI1, rather than EVI1, could be the normal gene. This possibility would be supported by the isolation of cDNA clones from normal libraries, and by homology analysis with the C. elegans protein egl-43.
Techniques such as FISH and RT-PCR have shown that EVI1 is involved in many more chromosomal rearrangements associated with myeloid leukemia than previously thought. Thus, EVI1 belongs to a growing number of promiscuous genes, such as TEL, AML1 and MLL, which are involved in a large number of chromosomal translocations with multiple partners. However, whereas TEL, AML1 and MLL are involved in lymphoblastic and myeloid leukemias, the involvement of EVI1 has been limited so far to myeloid leukemia only, suggesting that there could be a specific pathway or step during myeloid differentiation which can be affected by EVI1.
